Tenaya Therapeutics Announces TN-201 IND Clearance and Anticipated 2023 Milestones
January 09, 2023 07:00 ET
|
Tenaya Therapeutics, Inc.
Phase 1b Clinical Trial for TN-201 in MYBPC3-associated HCM Patients Expected to Begin Dosing in Third Quarter 2023; Data Anticipated in 2024 Data from First-in-Human Clinical Trial of TN-301...
Curative Biotechnology Announces Completion of IND Enabling Reformulated Metformin HCL Eye Drop Study
January 05, 2023 07:50 ET
|
Curative Biotechnology, Inc.
Boca Raton, FL, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel treatments...
Crystal Research Update Highlights 100% Responders Rate in Mild to Moderate COVID-19 Trial
December 28, 2022 07:00 ET
|
BIOXYTRAN, INC.
Trial meets endpoints in safety and efficacyIND Letter from the CDSCO to optimize dosageEstablishment of an Indian Subsidiary to commercialize ProLectin-M BOSTON, MASSACHUSETTS, Dec. 28,...
FDA Grants Ehave Consent to Proceed With Its Clinical Study on Intravenous Ketamine Infusion for Major Depressive Disorder
December 15, 2022 08:00 ET
|
Ehave
MIAMI, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a Healthcare Analytics provider with interests in the psychedelic and mental health sectors, announced today...
SparingVision’s lead asset SPVN06 clears IND application in the US for the treatment of retinitis pigmentosa
December 01, 2022 07:00 ET
|
SparingVision
SparingVision’s lead asset SPVN06 clears IND application in the US for the treatment of retinitis pigmentosa SparingVision set to advance into the clinic with breakthrough gene-independent approach...
First Wave BioPharma Chairman and CEO Issues Letter to Stockholders
November 16, 2022 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Nov. 16, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
NKGen Biotech Receives IND Clearance from FDA for SNK02 Allogeneic Natural Killer Cell Therapy for Solid Tumors
October 17, 2022 14:27 ET
|
NKGen Biotech
SANTA ANA, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc., a biotechnology company harnessing the power of the body’s immune system through the development of natural killer (NK) cell...
aTyr Pharma Announces Notice of Allowance for U.S. Patent for Anti-Neuropilin-2 (NRP2) Monoclonal Antibodies
September 29, 2022 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...
ROSEN, A TOP RANKED LAW FIRM, Encourages Kiromic BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – KRBP
August 16, 2022 14:53 ET
|
The Rosen Law Firm PA
NEW YORK, Aug. 16, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of...
Qualigen Therapeutics Announces Partnership with Hande Sciences To Scale-Up Manufacturing To Support IND-Enabling Studies for QN-302
July 06, 2022 09:00 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...